pIRES2-EGFP-p53 WT Citations (5)

Originally described in: The human DeltaNp53 isoform triggers metabolic and gene expression changes that activate mTOR and alter mitochondrial function.
Lin SC, Karoly ED, Taatjes DJ Aging Cell. 2013 Oct;12(5):863-72. doi: 10.1111/acel.12108. Epub 2013 Jun 25. PubMed Journal

---

Articles Citing pIRES2-EGFP-p53 WT

Articles
A New Regulatory Mechanism Between P53 And YAP Crosstalk By SIRT1 Mediated Deacetylation To Regulate Cell Cycle And Apoptosis In A549 Cell Lines. Yuan F, Wang J, Li R, Zhao X, Zhang Y, Liu B, Lei Y, Hu Y. Cancer Manag Res. 2019 Sep 23;11:8619-8633. doi: 10.2147/CMAR.S214826. eCollection 2019. PubMed
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, Nemejcova K, Bartu M, Jaksa R, Dura M, Kanwal M, Martinikova AS, Macurek L, Zemankova P, Kleibl Z, Dundr P. Sci Rep. 2019 Nov 19;9(1):17050. doi: 10.1038/s41598-019-53636-x. PubMed
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability. Guiley KZ, Shokat KM. Cancer Discov. 2023 Jan 9;13(1):56-69. doi: 10.1158/2159-8290.CD-22-0381. PubMed
NUDT22 promotes cancer growth through pyrimidine salvage. Walter M, Mayr F, Hanna BMF, Cookson V, Mortusewicz O, Helleday T, Herr P. Oncogene. 2023 Apr;42(16):1282-1293. doi: 10.1038/s41388-023-02643-4. Epub 2023 Mar 4. PubMed
The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53. Kelishadi M, Shahsavarani H, Tabarraei A, Shokrgozar MA, Teimoori-Toolabi L, Azadmanesh K. PLoS One. 2023 Oct 20;18(10):e0286231. doi: 10.1371/journal.pone.0286231. eCollection 2023. PubMed

If you have published an article using this material, please email us at to have your article added to this page.